Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Sponsor
National Health Research Institutes, Taiwan
Study ID
NCT04180072
Status
Active Not Recruiting

Conditions

  • Carcinoma, Hepatocellular

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab 1200 mg IV on day 1 every 3 weeks
  • Bevacizumab — DRUG
    Bevacizumab 15 mg/kg IV on day 1 every 3 weeks

Study Details

This is a single-arm clinical trial. The main objective is to determine the efficacy of atezolizumab+bevacizumab therapy in patients with advanced hepatocellular carcinoma and with chronic hepatitis B virus infection. All eligible patients will receive atezolizumab + bevacizumab therapy.

Key Dates

Start date
Mar 12, 2020
Status verified
Dec 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
51 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab plus bevacizumab
    Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Study treatment will continue until documented tumor progression or occurrence of unacceptable toxicity.

Primary Outcome Measure

Best overall response rate [ Time Frame: The last patient in has been treated for 6 months. All patients who have a PR or CR before that are responders ]

Related Studies